Investors & Media

Investor Relations

Day High
Day Low
4:00 PM ET on Dec 15, 2017
Stock price graph

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor for various hematologic malignancies. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with TG-101 also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monocloncal antibody into Phase 2 development and aims to bring additional preclinical pipeline assets into the clinic in the future. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX".

Currently, TG Therapeutics uses the following social media channels:
- Twitter

View all »   RSSRecent Releases

Dec 11, 2017
TG Therapeutics, Inc. Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting

Dec 8, 2017
TG Therapeutics, Inc. Recaps Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting